Fusion of the molecular adjuvant C3d to cleavage-independent native-like HIV-1 Env trimers improves the elicited antibody response
暂无分享,去创建一个
L. Stamatatos | R. Wyatt | D. Nemazee | A. Ward | C. Cottrell | M. Alirezaei | T. Ota | K. Tran | J. Guenaga | S. Bale | Lifei Yang | R. Wilson | Esmeralda D. Doyle | Wenjuan Li
[1] J. C. Love,et al. Low protease activity in B cell follicles promotes retention of intact antigens after immunization , 2023, Science.
[2] B. Pulendran,et al. Emerging concepts in the science of vaccine adjuvants , 2021, Nature reviews. Drug discovery.
[3] J. Mascola,et al. Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability , 2019, Immunity.
[4] J. Mullikin,et al. Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization , 2019, Cell.
[5] Kôzô Inoue. With Complement , 2018, Journal of Innate Immunity.
[6] R. Wyatt,et al. Structure-Guided Redesign Improves NFL HIV Env Trimer Integrity and Identifies an Inter-Protomer Disulfide Permitting Post-Expression Cleavage , 2018, Front. Immunol..
[7] D. Burton,et al. HIV-1 vaccine design through minimizing envelope metastability , 2018, Science Advances.
[8] R. Wyatt,et al. Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies , 2018, Front. Immunol..
[9] John P. Moore,et al. Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro , 2018, Journal of Virology.
[10] Daniel W. Kulp,et al. Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline‐Targeting HIV Vaccine Immunogens , 2018, Immunity.
[11] D. Weissman,et al. Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization , 2018, Virology.
[12] John P. Moore,et al. Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers , 2017, The Journal of Biological Chemistry.
[13] R. Wyatt,et al. Glutaraldehyde Cross-linking of HIV-1 Env Trimers Skews the Antibody Subclass Response in Mice , 2017, Front. Immunol..
[14] Daniel W. Kulp,et al. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding , 2017, Nature Communications.
[15] Daniel W. Kulp,et al. Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches , 2017, Immunity.
[16] R. Wyatt,et al. Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses , 2017, Journal of Virology.
[17] R. Koup,et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake , 2017, Science Translational Medicine.
[18] John P. Moore,et al. Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers , 2017, Journal of Virology.
[19] R. Wyatt,et al. Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein , 2017, Immunity.
[20] Richard T. Wyatt,et al. Particulate Array of Well‐Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach , 2017, Immunity.
[21] P. Zhu,et al. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses. , 2017, Vaccine.
[22] John P. Moore,et al. Native‐like Env trimers as a platform for HIV‐1 vaccine design , 2017, Immunological reviews.
[23] Ian A Wilson,et al. The HIV‐1 envelope glycoprotein structure: nailing down a moving target , 2017, Immunological reviews.
[24] R. Wyatt,et al. Evolution of B cell analysis and Env trimer redesign , 2017, Immunological reviews.
[25] Rafael Fernandez-Leiro,et al. A pipeline approach to single-particle processing in RELION , 2016, bioRxiv.
[26] John P. Moore,et al. Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C , 2016, PLoS pathogens.
[27] Bryan Briney,et al. Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. , 2016, Cell reports.
[28] R. Wyatt,et al. Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies , 2016, PLoS pathogens.
[29] D. Burton,et al. Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability , 2016, Nature Communications.
[30] R. Wyatt,et al. High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. , 2016, Cell reports.
[31] R. Wyatt,et al. Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers , 2015, Journal of Virology.
[32] J. Mascola,et al. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody , 2015, Journal of Virology.
[33] John P. Moore,et al. Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes , 2015, Cell.
[34] John P. Moore,et al. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity , 2015, Journal of Virology.
[35] G. Debnath,et al. D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers , 2016 .
[36] John R Mascola,et al. Antibody responses to envelope glycoproteins in HIV-1 infection , 2015, Nature Immunology.
[37] R. Wyatt,et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. , 2015, Cell reports.
[38] U. Baxa,et al. Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env , 2015, Journal of Virology.
[39] R. Wyatt,et al. Well-Ordered Trimeric HIV-1 Subtype B and C Soluble Spike Mimetics Generated by Negative Selection Display Native-like Properties , 2015, PLoS pathogens.
[40] John P. Moore,et al. A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.
[41] T. Vedvick,et al. Working together: interactions between vaccine antigens and adjuvants , 2013, Therapeutic advances in vaccines.
[42] L. Stamatatos,et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.
[43] J. Mascola,et al. Anti-HIV B Cell Lines as Candidate Vaccine Biosensors , 2012, The Journal of Immunology.
[44] P. Zhou,et al. Trimeric Glycosylphosphatidylinositol-Anchored HCDR3 of Broadly Neutralizing Antibody PG16 Is a Potent HIV-1 Entry Inhibitor , 2012, Journal of Virology.
[45] M. Carroll,et al. Regulation of humoral immunity by complement. , 2012, Immunity.
[46] P. Zhu,et al. HIV-1 Virus-Like Particles Produced by Stably Transfected Drosophila S2 Cells: a Desirable Vaccine Component , 2012, Journal of Virology.
[47] D. Isenman,et al. A Crystal Structure of the Complex Between Human Complement Receptor 2 and Its Ligand C3d , 2011, Science.
[48] S. Degn,et al. Trafficking of B cell antigen in lymph nodes. , 2011, Annual review of immunology.
[49] R. Coffman,et al. Vaccine adjuvants: putting innate immunity to work. , 2010, Immunity.
[50] J. Mascola,et al. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates , 2010, The Journal of experimental medicine.
[51] B. Haynes,et al. HIV-1 Envelope Induces Memory B Cell Responses That Correlate with Plasma Antibody Levels after Envelope gp120 Protein Vaccination or HIV-1 Infection1 , 2009, The Journal of Immunology.
[52] David N Mastronarde,et al. Automated electron microscope tomography using robust prediction of specimen movements. , 2005, Journal of structural biology.
[53] J. Sodroski,et al. Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d. , 2005, Virology.
[54] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[55] J. Sodroski,et al. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. , 2004, Virology.
[56] D. Montefiori,et al. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. , 2001, AIDS research and human retroviruses.
[57] J. Sodroski,et al. Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins , 2000, Journal of Virology.
[58] J. Sodroski,et al. Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution , 2000, Journal of virology.
[59] B. Nagar,et al. X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. , 1998, Science.
[60] M G Rossmann,et al. Structure of bacteriophage T4 fibritin: a segmented coiled coil and the role of the C-terminal domain. , 1997, Structure.
[61] J. Mascola,et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160 , 1997, Journal of virology.
[62] Christopher C. Goodnow,et al. C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity , 1996, Science.